FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3145987726> ?p ?o ?g. }

• W3145987726 abstract "BACKGROUND& AIMS: Gastric cancer is the fourth most common cancer and the second leading cause of cancer deaths worldwide. Despite improvements in chemotherapy and introduction of molecular targeted therapy, the prognosis of patients with unresectable or metastatic gastric cancer remains poor. Novel approaches for gastric cancer treatment are thus urgently needed. Combinatorial strategy can provide dramatic improvements over monotherapies. Targeting of protein phosphatase 2A (PP2A), a ubiquitous serine/threonine phosphatase with broad substrate specificity, has shown promising efficacy in combination with chemo-therapy and radiotherapy. In this study, we systematically analyzed synergism between LB-100, a PP2A inhibitor, and chemotherapeutic agents in the treatment of gastric cancer.METHODS:The effect of LB-100 on a panel of gastric cancer cell lines was determined by cell viability assay, colony formation assay and the xCELLigence system. The synergism between LB-100 and four chemotherapeutic drugs (Cisplatin, Docetaxel, Doxorubicin and 5-Fluorouracil), as assessed by cell viability and colony formation assays, was determined by isobologram analysis and quantified using the combination index (CI). The effect of monoand combination therapieson cytokinetic parameters, including apoptosis induction and cell cycle arrest, was evaluated. Activation of the apoptosis cascade and alternations in the cell cycle-associated proteins were investigated by western blot. RESULTS: As a single agent, LB-100 inhibited the growth of gastric cancer cells with IC50 values between 0.5 and 10μM. Real time cell viability measurement by using the xCELLigence system showed that LB-100 caused rapid cell death within the first two hours of treatment. Analysis of the synergism between LB-100 and four chemotherapeutic drugs including Cisplatin (DNA damaging agent), Docetaxel (anti-mitotic agent), Doxorubicin (topoisomerase poison) and 5-Fluorouracil (anti-metabolite), revealed that LB-100 potently synergized with Docetaxel (CI: 0.13 to 0.83) and Doxorubicin (CI: 0.32 to 0.66) in inhibiting gastric cancer cell growth. On the other hand, it was ineffective as a sensitizing agent for Cisplatin and 5Fluorouracil (CI>1). For both anticancer drugs (Docetaxel and Doxorubicin), co-treatment with LB-100 significantly enhanced the induction of apoptosis and cell cycle arrest at G2/M phase. These were confirmed by the observations thatthe drug combination treatment induced an increased activation of pro-apoptosis caspase-9-dependent cascade and decreased expression of key cell cycle regulators cyclin D1 and cyclin D3. CONCLUSIONS: Our results demonstrated that LB-100 is a potent sensitizing agent for chemotherapeutic drugs and support further exploration of PP2A inhibition as a novel drug combination regimen with Docetaxel or Doxorubicin in the treatment of gastric cancer." @default.
• W3145987726 created "2021-04-13" @default.
• W3145987726 creator A5000059613 @default.
• W3145987726 creator A5000326895 @default.
• W3145987726 creator A5004036490 @default.
• W3145987726 creator A5021065048 @default.
• W3145987726 creator A5057064728 @default.
• W3145987726 creator A5069893086 @default.
• W3145987726 creator A5082118905 @default.
• W3145987726 creator A5082620123 @default.
• W3145987726 creator A5088985185 @default.
• W3145987726 creator A5091692002 @default.
• W3145987726 date "2015-01-01" @default.
• W3145987726 modified "2023-09-27" @default.
• W3145987726 title "Su1991 Surveillance Strategy Based on the Incidence and Patterns of Recurrence After Curative Endoscopic Submucosal Dissection for Early Gastric Cancer" @default.
• W3145987726 hasPublicationYear "2015" @default.
• W3145987726 type Work @default.
• W3145987726 sameAs 3145987726 @default.
• W3145987726 citedByCount "0" @default.
• W3145987726 crossrefType "journal-article" @default.
• W3145987726 hasAuthorship W3145987726A5000059613 @default.
• W3145987726 hasAuthorship W3145987726A5000326895 @default.
• W3145987726 hasAuthorship W3145987726A5004036490 @default.
• W3145987726 hasAuthorship W3145987726A5021065048 @default.
• W3145987726 hasAuthorship W3145987726A5057064728 @default.
• W3145987726 hasAuthorship W3145987726A5069893086 @default.
• W3145987726 hasAuthorship W3145987726A5082118905 @default.
• W3145987726 hasAuthorship W3145987726A5082620123 @default.
• W3145987726 hasAuthorship W3145987726A5088985185 @default.
• W3145987726 hasAuthorship W3145987726A5091692002 @default.
• W3145987726 hasConcept C11960822 @default.
• W3145987726 hasConcept C121608353 @default.
• W3145987726 hasConcept C126322002 @default.
• W3145987726 hasConcept C143998085 @default.
• W3145987726 hasConcept C178666793 @default.
• W3145987726 hasConcept C190283241 @default.
• W3145987726 hasConcept C2776694085 @default.
• W3145987726 hasConcept C2778239845 @default.
• W3145987726 hasConcept C2781190966 @default.
• W3145987726 hasConcept C29537977 @default.
• W3145987726 hasConcept C31573885 @default.
• W3145987726 hasConcept C389152 @default.
• W3145987726 hasConcept C502942594 @default.
• W3145987726 hasConcept C53227056 @default.
• W3145987726 hasConcept C55493867 @default.
• W3145987726 hasConcept C71924100 @default.
• W3145987726 hasConcept C86803240 @default.
• W3145987726 hasConcept C96232424 @default.
• W3145987726 hasConceptScore W3145987726C11960822 @default.
• W3145987726 hasConceptScore W3145987726C121608353 @default.
• W3145987726 hasConceptScore W3145987726C126322002 @default.
• W3145987726 hasConceptScore W3145987726C143998085 @default.
• W3145987726 hasConceptScore W3145987726C178666793 @default.
• W3145987726 hasConceptScore W3145987726C190283241 @default.
• W3145987726 hasConceptScore W3145987726C2776694085 @default.
• W3145987726 hasConceptScore W3145987726C2778239845 @default.
• W3145987726 hasConceptScore W3145987726C2781190966 @default.
• W3145987726 hasConceptScore W3145987726C29537977 @default.
• W3145987726 hasConceptScore W3145987726C31573885 @default.
• W3145987726 hasConceptScore W3145987726C389152 @default.
• W3145987726 hasConceptScore W3145987726C502942594 @default.
• W3145987726 hasConceptScore W3145987726C53227056 @default.
• W3145987726 hasConceptScore W3145987726C55493867 @default.
• W3145987726 hasConceptScore W3145987726C71924100 @default.
• W3145987726 hasConceptScore W3145987726C86803240 @default.
• W3145987726 hasConceptScore W3145987726C96232424 @default.
• W3145987726 hasLocation W31459877261 @default.
• W3145987726 hasOpenAccess W3145987726 @default.
• W3145987726 hasPrimaryLocation W31459877261 @default.
• W3145987726 hasRelatedWork W116681096 @default.
• W3145987726 hasRelatedWork W1849056430 @default.
• W3145987726 hasRelatedWork W1975851074 @default.
• W3145987726 hasRelatedWork W2032370832 @default.
• W3145987726 hasRelatedWork W2041011201 @default.
• W3145987726 hasRelatedWork W2049804579 @default.
• W3145987726 hasRelatedWork W2077013844 @default.
• W3145987726 hasRelatedWork W2081557098 @default.
• W3145987726 hasRelatedWork W2091881893 @default.
• W3145987726 hasRelatedWork W2101764483 @default.
• W3145987726 hasRelatedWork W2111834197 @default.
• W3145987726 hasRelatedWork W2117019982 @default.
• W3145987726 hasRelatedWork W2159074485 @default.
• W3145987726 hasRelatedWork W2165796624 @default.
• W3145987726 hasRelatedWork W2389009399 @default.
• W3145987726 hasRelatedWork W2590355988 @default.
• W3145987726 hasRelatedWork W2906823192 @default.
• W3145987726 hasRelatedWork W2978003164 @default.
• W3145987726 hasRelatedWork W2997758331 @default.
• W3145987726 hasRelatedWork W3091203822 @default.
• W3145987726 isParatext "false" @default.
• W3145987726 isRetracted "false" @default.
• W3145987726 magId "3145987726" @default.
• W3145987726 workType "article" @default.